SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes In Vitro SCO-267 (CHO cells) activates the Gα q , Gα s , and Gα 12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: N-STZ rats Dosage: 1 or 10 mg/kg Administration: P.o.; Result: Improved insulin sensitivity and exerted sustained glucose-lowering effect. Form:Solid IC50& Target:GPR40
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
SCO-267
CAS number：1656261-09-4 molecular formula：C36H46N4O5
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1656261-09-4 | molecular formula | C36H46N4O5 |
| molecular weight | 614.77 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
